Shuttle Pharmaceuticals (NASDAQ:SHPH) Announces Quarterly Earnings Results

Shuttle Pharmaceuticals (NASDAQ:SHPH) released its quarterly earnings results on Thursday. The company reported ($3.10) earnings per share for the quarter, FiscalAI reports.

Shuttle Pharmaceuticals Price Performance

NASDAQ SHPH traded up $0.30 during midday trading on Thursday, hitting $3.90. 17,428 shares of the company traded hands, compared to its average volume of 865,370. The company’s 50-day simple moving average is $3.58 and its 200-day simple moving average is $5.52. Shuttle Pharmaceuticals has a 52 week low of $2.58 and a 52 week high of $55.90. The company has a market cap of $2.48 million, a PE ratio of -0.08 and a beta of 0.21.

Analysts Set New Price Targets

SHPH has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Insider Transactions at Shuttle Pharmaceuticals

In other Shuttle Pharmaceuticals news, major shareholder Financial Lp Hrt acquired 8,266 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average cost of $3.38 per share, for a total transaction of $27,939.08. Following the completion of the transaction, the insider owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. The trade was a 15.81% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders bought 53,398 shares of company stock valued at $181,764 and sold 38,133 shares valued at $132,128. Insiders own 0.36% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc is a clinical-stage specialty pharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer patients. The company’s research centers on radiosensitizers, which are intended to make tumor cells more sensitive to radiation while helping preserve surrounding healthy tissue.

Shuttle’s lead product candidate is ropidoxuridine, an orally administered investigational therapy being developed for use in combination with radiation therapy.